Michael Neely, MD, MSc, FCP

Chief, Division of Infectious Diseases
Director, Laboratory of Applied Pharmacokinetics and Bioinformatics, The Saban Research Institute
Investigator, Infectious Diseases
Attending Physician
Professor of Pediatrics and Clinical Scholar, Keck School of Medicine of USC

Dr. Neely is a Board-certified pediatric infectious disease specialist with more than 20 years of experience in patient care and research. He serves as the Chief of the Division of Infectious Diseases at CHLA. He is Director of the CHLA Laboratory of Applied Pharmacokinetics and Bioinformatics, making him one of the world leaders in creating models of drug behavior that help identify the best drug dose for an individual patient to achieve the desired concentrations in the body. Through his work at The Saban Research Institute, he leads internationally recognized research efforts in pediatric clinical pharmacology and infectious diseases.

Dr. Neely received his medical degree from the University of California, Davis, and completed an internship and residency at Rainbow Babies and Children’s Hospital, University Hospitals of Cleveland in Ohio. In 2002, he completed two fellowships in the Divisions of Pediatric Infectious Diseases and Pediatric Pharmacology, both also from the Rainbow Babies and Children’s Hospital, University Hospitals of Cleveland. He is a Professor of Pediatrics and Clinical Scholar at the Keck School of Medicine of the University of Southern California. He lectures internationally and has published more than 100 peer-reviewed publications as well as nine book chapters.

Clinical Interests

Complex infections and therapeutic dilemmas


Medical School

University of California, Davis


Pediatrics, Rainbow Babies and Children's Hospital, Cleveland, OH


Pediatrics, Rainbow Babies and Children's Hospital, Cleveland, OH


Pediatric Infectious Diseases and Clinical Pharmacology, Rainbow Babies and Children's Hospital, Cleveland, OH



Pediatric Infectious Diseases: American Board of Pediatrics

Professional Memberships

Elected to the Society for Pediatric Research, the American Pediatric Society, and a Fellow in the American College of Clinical Pharmacology


Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL; on behalf of The International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases. Individualized antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014 Jun;14(6):498-509. doi: 10.1016/S1473-3099(14)70036-2. Epub 2014 Apr 24. Review.

Felton TW, Roberts JA, Lodise TP, Van Guilder M, Boselli E, Neely MN, Hope WW. Individualization of Dosing of Piperacillin for Critically Ill Patients: Dosing Software to Optimize Antimicrobial Therapy. Antimicrob Agents Chemother. 2014 May 5. [Epub ahead of print]

Wang NY, Patras KA, Seo HS, Cavaco CK, Rösler B, Neely MN, Sullam PM, Doran KS. Group B Streptococcal Serine-Rich Repeat Proteins Promote Interaction with Fibrinogen and Vaginal Colonization. J Infect Dis. 2014 Apr 15. [Epub ahead of print]

Kortum AN, Rodriguez-Nunez I, Yang J, Shim J, Runft D, O'Driscoll ML, Haire RN, Cannon JP, Turner PM, Litman RT, Kim CH, Neely MN, Litman GW, Yoder JA. Differential expression and ligand binding indicate alternative functions for zebrafish polymeric immunoglobulin receptor (pIgR) and a family of pIgR-like (PIGRL) proteins. Immunogenetics. 2014 Apr;66(4):267-79. doi: 10.1007/s00251-014-0759-4. Epub 2014 Jan 28.

Rowe HM, Withey JH, Neely MN. Zebrafish as a model for zoonotic aquatic pathogens. Dev Comp Immunol. 2014 Sep;46(1):96-107. doi: 10.1016/j.dci.2014.02.014. Epub 2014 Mar 6. Review.


Personalized medicine, optimum dosing of antibiotics and other medications in children, diagnosis and therapy of Mycobacterium abscessus infections in children with cystic fibrosis